Maeda et al. reported that stage I patients with lung adenocarcinoma lacking the expression of either MYH9 or vimentin have a favorable outcome without postoperative adjuvant chemotherapy [14]. This evidence concerns the gene MYH9 and lung adenocarcinoma.